IMIDomics to license TNAX’s drug candidate for IMIDsIMIDs

07 Sep 2023
www.pharmaceutical-technology.com
License out/inADC
IMIDomics to license TNAX’s drug candidate for IMIDs
Preview
Source: Pharmaceutical Technology
IMIDomics will expedite the development of the antibody to exploit its potential across various immune-mediated inflammatory diseases. Credit: National Cancer InstituteCancer Institute on Unsplash.
IMIDomics has entered an exclusive agreement to license TNAX Biopharma’s drug candidate, IMB1001, to potentially treat immune-mediated inflammatory diseases (IMIDs).
As per the deal, IMIDomics will gain access to global rights for the development, production, marketing and sub-licensing of IMB1001 from TNAX.
Recommended Reports
IMIDomics to license TNAX’s drug candidate for IMIDs
Preview
Source: Pharmaceutical Technology
ReportsClostridium difficile Toxin B (toxB or EC 3.4.22.) Drugs in Development by Therapy Areas and Indi... GlobalData
IMIDomics to license TNAX’s drug candidate for IMIDs
Preview
Source: Pharmaceutical Technology
ReportsClostridium difficile Toxin A (toxA or EC 3.4.22.) Drugs in Development by Therapy Areas and Indi... GlobalData
View all
A humanised antibody that acts on CD226, IMB1001 is currently in the preclinical development stage.
The agreement comprises all patents, rights and information linked to the drug candidate, including its usage in humans as well as animals.
The companies did not divulge the financial terms of the deal but it is said to comprise upfront, milestone and royalty payments.
IMIDomics chief development officer H Daniel Perez said: “In licensing this promising new drug candidate, we are demonstrating our commitment to applying our proprietary Clinical Discovery Engine in service of discovering and developing impactful medicines for IMID patients and underscoring our confidence in the potential of this therapeutic candidate.
“The licence of IMB1001 from TNAXTNAX accelerated our efforts to translate our scientific discoveries into meaningful therapeutic options.”
IMIDomics detected the CD226 target by leveraging its data-powered platform, Clinical Discovery Engine, to explore IMIDsIMIDs’ underlying processes.
A transmembrane glycoprotein, CD226 has a key role in the immune response.
IMB1001 is said to possess wider applicability across various ailments, especially for patients who are unresponsive or intolerant to the existing standard of care treatments.
IMIDomics will expedite the development of this antibody to exploit its potential across various IMIDsIMIDs.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.